Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RRS HA Long Lasting is a sterile Class III medical device developed by Skin Tech Pharma Group for aesthetic soft-tissue augmentation and wrinkle reduction. It is a hybrid dermal filler and skin booster composed of 21 mg of cross-linked, biotechnological non-animal origin hyaluronic acid (HA) in a 3 mL syringe, solubilized in a protective buffer solution containing 15 amino acids with antioxidant and hydrating properties. The product is manufactured using the proprietary UnHeating technological process (UHI), which optimizes BDDE cross-linking at lower temperatures to create a highly stable hydrogel resistant to degradation. It is indicated for treating skin photoaging, dermal atrophy, and skin depressions, providing both physical volumizing and biorevitalizing effects that typically last 9 to 12 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RRS HA Long Lasting.